Waters Corporation reports recurring developments across life sciences and diagnostics, including analytical instruments, informatics, service, and high-volume testing workflows. News for WAT commonly covers operating results and guidance, the Analytical Sciences Division, and the Biosciences and Diagnostic Solutions businesses added through the completed BD transaction.
Company updates also include product launches for liquid chromatography, UPLC and UHPLC workflows, MALS detection, rheometry, LC columns, and TA Instruments technologies. Diagnostic news includes FDA-related developments for the Onclarity HPV Self-Collection Kit and BD Onclarity HPV Assay, along with commercial, conference, and shareholder-related updates.
Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., President and CEO, will speak in a fireside chat at the TD Cowen Health Care Conference on March 2, 2026 at 11:10 AM ET.
A live webcast will stream on the company's Events & Presentations investor site and a replay will be available for 90 days.
Waters (NYSE: WAT) launched 1 mm I.D. microflow LC columns with MaxPeak Premier Technology on February 17, 2026, for ACQUITY, BioResolve, and GTxResolve brands. The columns claim up to 2× higher sensitivity, use up to 75% less sample, and reduce solvent use by up to 4× versus 2.1 mm I.D. columns, improving recovery for small molecules, peptides, and oligonucleotides while enabling earlier reproducible results and global availability with immediate shipment.
BD (NYSE: BDX) completed the spin-off and combination of its Biosciences & Diagnostic Solutions business with Waters Corporation (NYSE: WAT) on Feb 9, 2026. BD received $4.0 billion in cash and shareholders received ~0.135 WAT shares per BDX share, with cash for fractions.
As of closing BD shareholders held 39.2% of the combined company (fully diluted). Based on WAT's Feb 6, 2026 close, the business was valued at $18.8 billion. BD expects to use $2.0 billion for an accelerated share repurchase and $2.0 billion to repay debt. Claire M. Fraser joined the Waters board and stepped down from the BD board.
Waters (NYSE: WAT) has completed its combination with Becton, Dickinson and Company's Biosciences & Diagnostic Solutions businesses, creating a global life sciences and diagnostics leader organized into four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences. The transaction used a Reverse Morris Trust, and post-close ownership is Waters 60.8% and BD shareholders 39.2% on a fully diluted basis. Claire M. Fraser, Ph.D., joined the Waters Board, expanding it to 11 members. Barclays advised Waters; Kirkland & Ellis served as lead counsel.
Waters Corporation (NYSE: WAT) reported Q4 2025 sales of $932 million, up 7% as reported (6% constant currency), with GAAP EPS $3.77 and non-GAAP EPS $4.53 (+10%). Full-year 2025 sales were $3,165 million (+7%) and non-GAAP EPS was $13.13 (+11%).
The company closed its acquisition of BD Biosciences and Diagnostic Solutions, expecting an owned-period contribution of approximately $3.0 billion and total 2026 reported revenue of $6.405–6.455 billion. 2026 non-GAAP EPS guidance is $14.30–14.50.
BD (NYSE: BDX) set Feb 5, 2026 as the record date for the spin-off of its Biosciences & Diagnostic Solutions business and expects to combine the spun-off unit with Waters (NYSE: WAT) via a Reverse Morris Trust on Feb 9, 2026, subject to customary closing conditions.
Under the terms, BD will receive $4 billion cash, and BD shareholders will receive Waters common stock representing 39.2% of the combined company on a fully diluted basis; Waters shareholders will own 60.8%.
Shares will trade with due bills starting Feb 5 and trade ex-distribution after closing; BD received a favorable IRS private letter ruling.
Waters (NYSE: WAT) shareholders approved issuing Waters common stock to shareholders of Becton, Dickinson and Company (NYSE: BDX) for the proposed combination of BD's Biosciences & Diagnostic Solutions business with Waters, with preliminary voting showing ~99% support.
Waters and BD received all required regulatory approvals and BD obtained a favorable IRS Private Letter Ruling on U.S. federal tax matters. The transaction is expected to close on February 9, 2026, subject to customary closing conditions. Waters will release Q4 2025 results and hold a conference call and webcast on February 9, 2026 at 8:30 a.m. ET; a replay will be available through at least March 9, 2026.
Waters Corporation (NYSE:WAT) will release Q4 2025 financial results and host a conference call on Thursday, February 12, 2026 at 8:00 AM ET. A live webcast will stream on the Waters Investor Relations site at https://ir.waters.com, and a replay will be available through March 12, 2026 (midnight ET).
Waters is a global provider of analytical instruments, separations technologies, and software serving life, materials, food, and environmental sciences for over 65 years, with more than 7,600 employees and operations in 100+ countries.
Waters Corporation (NYSE:WAT) said Udit Batra, Ph.D., President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 2:15 PM PT (5:15 PM ET).
A live webcast will be available on the company’s Events & Presentations page at https://ir.waters.com, and a replay will be accessible for 90 days. Waters is a global provider of analytical instruments, separations technologies, and software serving life, materials, food, and environmental sciences.
Waters Corporation (NYSE:WAT) said CEO Udit Batra, Ph.D. will take part in a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 2:30 PM GMT (9:30 AM ET).
A live webcast will be available on the company's Events & Presentations investor relations site (https://ir.waters.com) and a replay will be posted for 90 days. Waters is described as a global leader in analytical instruments, separations technologies, and software, operating in over 100 countries with more than 7,600 employees and over 65 years of history.